In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Headquartered in Allschwil, a town on the western suburb of Basel, Switzerland, Actelion was an industry leader in the field of pulmonary hypertension (PH), and most notably, pulmonary arterial hypertension (PAH) for the last two decades.
Actelion has been fully integrated into Janssen, and we have now transitioned to our corporate identity to Janssen, and Pulmonary Hypertension is one of our six therapeutic areas. You can click on each country to see their 2018 and 2019 Transfer of Value data. The Pulmonary Hypertension activities will be included within the Janssen Transfer of Value data as of 2020 for all countries.
To learn more about PH, Janssen Pulmonary Hypertension and its medicines, please visit www.janssen.com/emea/therapeutic-areas/pulmonary-hypertension or follow @JanssenEMEA